• 1
    McConnell JD, Brusketwitz R, Walsh P, Andriole G, Lieber M, Holtgrewe L, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338:55763.
  • 2
    Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (Dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:43441.
  • 3
    Otberg N, Finner AM, Shapiro J. Androgenetic alopecia. Endocrinol Metab Clin North Am 2007;36:37998.
  • 4
    Marks LS, Partin AW, Dorey FJ, Gormley GJ, Epstein JI, Garris JB, Macairan ML, Shery ED, Santos PB, Stoner E, Dekernion JB. Long-term effects of finasteride on prostate tissue composition. Urology 1999;53:57480.
  • 5
    Debruyne F, Barkin J, Van Erps P, Reis M, Tammela TL, Roehrborn C. Efficacy and safety of long-term treatment with 5-alpha-reductase inhibitor of dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46:48895.
  • 6
    Andriole G, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS. Effect of Dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192202.
  • 7
    Walsh PC. Chemoprevention of prostate cancer. N Engl J Med 2010;362:12378.
  • 8
    Qiu Y, Yanase T, Hu H, Tanaka T, Nishi Y, Liu M, Sueishi K, Sawamura T, Nawata H. Dihydrotestosterone suppresses foam cell formation and attenuates atherosclerosis development. Endocrinology 2010;151:330716.
  • 9
    Russell DW, Wilson JD. Steroid 5α-reductase: Two genes/Two enzymes. Annu Rev Biochem 1994;63:2561.
  • 10
    Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV. Unique preclinical characteristic of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 1997;282:1496502.
  • 11
    Dubrovsky B. Neurosteroids, neuroactive steroids, and symptoms of affective disorders. Pharmacol Biochem Behav 2006;84:64455.
  • 12
    Baulieu EE. Neurosteroids: A novel function of the brain. Psychoneuroendocrino 1998;23:96387.
  • 13
    Tsuruo Y. Topography and function of androgen-metabolizing enzymes in the central nervous system. Anat Sci Int 2005;80:111.
  • 14
    Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia. World J Urol 2002;19:41325.
  • 15
    Gormley GJ, Stoner E, Brusketwitz RC, Imperato-McGinley J, Walsh P, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J. The effect of finasteride in men with benign prostatic hyperplasia. J Urol 1992;167:11027.
  • 16
    Lepart ED. Age-related changes in brain and pituitary 5alpha-reductase with finasteride(proscar) treatment. Neurobiol Aging 1995;16:64750.
  • 17
    Andersson S, Berman DM, Jenkins EP, Russell DW. Deletion of 5α-reductase 2 gene in male pseudohermaphroditism. Nature 1991;354:15961.
  • 18
    Jenkins EP, Andersson S, Imperato-McGinley J, Wilson JD, Russell DW. Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J Clin Invest 1992;89:293300.
  • 19
    Iehle C, Delos S, Guirou O, Tate R, Raynaud JP, Martin PM. Human prostatic steroid 5α-reductase isoforms-a comparative study of selective inhibitors. J Steroid Biochem Molec Biol 1995;54:2739.
  • 20
    Bull HG, Garcia-Calvo M, Andersson S, Baginsky WF, Chan HK, Ellsworth DE, Miller RR, Stearns RA, Bakshi RK, Rasmusson GH, Tolman RL, Myers RW, Kozarich JW, Harris GS. Mechanism-based inhibition of human steroid 5α-reductase by finasteride: Enzyme-catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor. J Am Chem Soc 1996;118:235965.
  • 21
    Drury JE, Costanzo LD, Penning TM, Christianson DW. Inhibition of human steroid 5β-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complex. J Biol Chem 2009;285:1978690.
  • 22
    Huskey SW, Dean DC, Miller RR, Rasmusson GH, Chiu SH. Identification of human cytochrome p450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab Dispos 1995;23:112635.
  • 23
    Stuart JD, Lee FW, Noel DS, Kadwell SH, Overton LK, Hoffman CR, Kost TA, Tippin TK, Teager RL, Batchelor KW, Bramson HN. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5α-reductases: Determinants for different in vivo activities of GI198745 and finasteride in the rat. Biochem Pharmacol 2001;62:93342.
  • 24
    Makridakis N, Reichardt JK. Pharmacogenetic analysis of human steroid 5α reductase type II: Comparison of finasteride and dutasteride. J Mol Endocrinol 2005;34:61723.
  • 25
    Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, Herlihy R, Fitch W, Labasky R, Auerbach S, Parra R, Rajfer J, Culbertson J, Lee M, Bach MA, Waldstreicher J, PLESS Study Group. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 2003;61:57984.
  • 26
    Erdemir F, Harbin A, Hellstrom WJ. 5-alpha reductase inhibitors and erectile dysfunction: The connection. J Sex Med 2008;5:291724.
  • 27
    Kaufman KD, Olsen EA, Whiting D. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol 1998;39:57889.
  • 28
    Leyden J, Dunlap F, Miller B, Winters P, Lebwohl M, Hecker D, Kraus S, Baldwin H, Shalita A, Draelos Z, Markou M, Thiboutot D, Rapaport M, Kang S, Kelly T, Pariser D, Webster G, Hordinsky M, Rietschel R, Katz I, Terranella L, Best S, Round E, Waldstreicher J. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 1999;40:9307.
  • 29
    Whiting DA, Olsen EA, Savin R, Halper L, Rodgers A, Wang L, Hustad C, Palmisano J. Male Pattern Hair Loss Study Group. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol 2003;13:15060.
  • 30
    Byrnes CA, Morton AS, Liss CL, Lippert MC, Gillenwater JY. Efficacy, tolerability, and effect on health-related quality of life of Finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: A community-based study. Clin Ther 1995;17:95669.
  • 31
    Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by Dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab 2004;89:217984.
  • 32
    Hudson PB, Boake R, Trachtenberg J, Romas NA, Rosenblatt S, Narayan P, Geller J, Lieber MM, Elhilali M, Norman R, Patterson L, Perreault JP, Malek GH, Bruskewitz RC, Roy JB, Ko A, Jacobsen CA, Stoner E. Efficacy of Finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The north American Finasteride study. Urology 1999;53:6905.
  • 33
    Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, Sweeney M, Grossman EB. Efficacy and tolerability of Doxazosin and Finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia. Urology 2003;61:11926.
  • 34
    Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ. The efficacy of Terazosin, Finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996;335:5339.
  • 35
    Lowe FC, McConnell JD, Hudson PB, Romas NA, Boake R, Lieber M, Elhilali M, Geller J, Imperto-McGinely J, Andriole GL, Bruskewitz RC, Walsh PC, Bartsch G, Nacey JN, Shah S, Pappas F, Ko A, Cook T, Stoner E, Waldstreicher J, Finasteride Study Group. Long-term 6-year experience with Finasteride in patients with benign prostatic hyperplasia. Urology 2003;61:7916.
  • 36
    Marberger MJ. Long-term effects of Finasteride in patients with benign prostatic hyperplasia: A double-blind placebo-controlled, multicenter study. Urology 1998;51:67786.
  • 37
    McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA. The long-term effect of Doxazosin, Finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:238798.
  • 38
    Tenover JL, Pagano GA, Morton AS, Liss CL, Byrnes CA. Efficacy and tolerability of Finasteride in symptomatic benign prostatic hyperplasia: A primary care study. Clin Ther 1997;19:24358.
  • 39
    Amory JK, Wang C, Swerdloff RS, Anawalt BD, Matsumoto AM, Bremner WJ, Walker SE, Haberer LJ, Clark RV. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab 2007;92:165965.
  • 40
    Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:21415.
  • 41
    Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B, Montorsi F, CombAT Study Group. The effects of Dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008;179:61621.
  • 42
    Amory JK, Anawalt BD, Matsumoto AM, Page ST. The effect of 5α-reductase inhibition with Dutasteride and Finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen, and sexual functions in healthy young men. J Urol 2008;179:23338.
  • 43
    Marberger MJ, Roehrborn CG, Marks LS, Wilson T, Rittmaster RS. Relationship among serum testosterone, sexual function, and response to treatment in men receiving Dutasteride for benign prostatic hyperplasia. J Clin Endocrinol Metab 2006;91:13238.
  • 44
    Siami P, Roehrborn CG, Barkin J, Damiao R, Wyczolkowski M, Duggan A, Major-Walker K, Morrill BB. Combination therapy with Dutasteride and Tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: The CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials 2007;28:7709.
  • 45
    Desgrandchamps F, Droupy S, Irani J, Saussine C, Comenducci A. Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice. BJU Int 2006;98:838.
  • 46
    AUA guidelines on management of benign prostatic hyperplasia. Chapter 1: Diagnosis and treatment recommendations. J Urol 2003;170:53047.
  • 47
    Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Cavazzi A, Bartoletti R. Finasteride 5 mg and sexual side effects: How many of these are related to a nocebo phenomenon? J Sex Med 2007;4:170812.
  • 48
    Canguven O, Burnett AL. The effect of 5α-reductase inhibitors on erectile function. J Androl 2008;29:51423.
  • 49
    Bruskewitz R, Girman CJ, Fowler J, Rigby OF, Sullivan M, Bracken RB, Fusilier HA, Kozlowski D, Kantor SD, Johnson EL, Wang DZ, Waldstreicher J. Effect of Finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. Urology 1999;54:6708.
  • 50
    Wilton L, Pearce G, Edet E, Freemantle S, Stephens MD, Mann RD. The safety of Finasteride used in benign prostatic hypertrophy: A non-interventional observational cohort study in 14,772 patients. BJU Int 1996;78:37984.
  • 51
    Watson V, Ryan M, Brown T, Barnett G, Ellis BW, Emberton M. Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2004;172:23215.
  • 52
    Traish AM, Goldstein I, Kim NN. Testosterone and erectile function: From basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. Eur Urol 2007;52:5470.
  • 53
    Traish AM, Guay AT. Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med 2006;3:382404.
  • 54
    Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 2009;30:1022.
  • 55
    Yassin AA, Saad F, Traish A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: A series of case reports. J Sex Med 2006;3:72735.
  • 56
    Carruthers M. The paradox dividing testosterone deficiency symptoms and androgen assays: A closer look at the cellular and molecular mechanisms of androgen action. J Sex Med 2008;5:9981012.
  • 57
    Mantzoros CS, Georgiadis EI, Trichopoulos D. Contribution of dihydrotestosterone to male sexual behaviour. BMJ 1995;310:128991.
  • 58
    Penson DF, Ng C, Rajfer J, Gonzalez-Cadavid NF. Adrenal control of erectile function and nitric oxide synthase in the rat penis. Endocrinology 1997;138:392532.
  • 59
    Garban H, Marquez D, Cai L, Rajfer J, Gonzalez-Cadavid NF. Restoration of normal adult penile erectile response in aged rats by long-term treatment with androgens. Biol Reprod 1995;53:136572.
  • 60
    Park KH, Kim SW, Kim KD, Paick JS. Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int 1999;83:32733.
  • 61
    Manzo J, Cruz MR, Hernandez ME, Pacheco P, Sachs BD. Regulation of noncontact erection in rats by gonadal steroids. Horm Behav 1999;35:26470.
  • 62
    Bialy M, Sachs BD. Androgen implants in medial amygdala briefly maintain noncontact erection in castrated male rats. Horm Behav 2002;42:34555.
  • 63
    Sachs BD. Placing erection in context: The reflexogenic-psychogenic dichotomy reconsidered. Neurosci Biobehav Rev 1995;19:21124.
  • 64
    Lugg JA, Rajfer J, Gonzalez-Cadavid NF. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology 1995;136:1495501.
  • 65
    Seo SI, Kim SW, Paick JS. The effects of androgen on penile reflex, erectile response to electrical stimulation and penile NOS acitivty in the rat. Asian J Androl 1999;1:16974.
  • 66
    Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of transdermal dihydrotestosterone in the aging male: A prospective, randomized, double blind study. J Clin Endocrinol Metab 2002;87:146772.
  • 67
    Green L, Wysowski DK, Fourcroy JL. Gynecomastia and breast cancer during Finasteride therapy. N Engl J Med 1996;335:823.
  • 68
    Vaughan C, Goldstein FC, Tenover JL. Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone. J Androl 2007;28:87582.
  • 69
    Thomas DB, Jimenez LM, McTiernan A, Rosenblatt K, Stalsberg H, Stemhagen A, Thompson WD, Curnen MG, Satariano W, Austin DF, Greenberg RS, Key C, Kolonel LN, West DW. Breast cancer in men: Risk factors with hormonal implications. Am J Epidemiol 1992;135:73448.
  • 70
    Barrett-Connor E, Von Muhlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: The Rancho Bernardo Study. J Clin Endocrinol Metab 1999;84:5737.
  • 71
    Seidman SN. The aging male: Androgens, erectile dysfunction, and depression. J Clin Psychiatry 2003;64 (Suppl):317.
  • 72
    Rizvi SJ, Kennedy SH, Ravindran LN, Giacobbe P, Eisfeld BS, Mancini D, McIntyre RS. The relationship between testosterone and sexual function in depressed and healthy men. J Sex Med 2010;7(Pt 1):81625.
  • 73
    Shores MM, Moceri VM, Sloan KL, Matsumoto AM, Kivlahan DR. Low testosterone levels predict incident depressive illness in older men: Effects of age and medical morbidity. J Clin Psychiatry 2005;66:714.
  • 74
    McIntyre RS, Mancini D, Eisfeld BS, Soczynska JK, Grupp L, Konarski JZ, Kennedy SH. Calculated bioavailable testosterone levels and depression in middle-aged men. Psychoneuroendocrinology 2006;31:102935.
  • 75
    Almeida OP, Yeap BB, Hankey GJ, Jamrozik K, Flicker L. Low free testosterone concentration as a potentially treatable cause of depressive symptoms in older men. Arch Gen Psychiatry 2008;65:2839.
  • 76
    Hintikka J, Niskanen L, Koivumaa-Honkanen H, Tolmunen T, Honkalampi K, Lehto SM, Viinamaki H. Hypogonadism, decreased sexual desire, and long-term depression in middle aged men. J Sex Med 2009;6:204957.
  • 77
    Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 2004;29:107181.
  • 78
    Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJG, Saad F, Kalinchenko SY. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 2010;7:257282.
  • 79
    Finn DA, Long SL, Tanchuck MA, Crabbe JC. Interaction of chronic ethanol exposure and finasteride: Sex and strain differences. Pharmacol Biochem Behav 2004;78:43543.
  • 80
    Purdy RH, Morrow AL, Moore PH, Paul SM. Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain. Proc Natl Acad Sci USA 1991;88:45537.
  • 81
    Rupprecht R, Holsboer F. Neuroactive steroids: Mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 1999;22:4106.
  • 82
    Amikishieva AV. GABA in regulation of communicative activity and sexual motivation of male mice with different psychoemotional status. Bull Exp Biol Med 2007;143:22530.
  • 83
    Henderson LP. Steroid modulation of GABAA receptor-mediated transmission in the hypothalamus: Effects on reproductive function. Neuropharmacology 2007;52:143953.
  • 84
    Ghoumari AM, Ibanez C, El-Etr M, Leclerc P, Eychenne B, O'Malley BW, Baulieu EE, Schumacher M. Progesterone and its metabolites increase myelin basic protein expression in organotypic slice cultures of rat cerebellum. J Neurochem 2003;86:84859.
  • 85
    Griffin LD, Gong W, Verot L, Mellon SH. Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat Med 2004;10:70411.
  • 86
    Ahmad I, Lope-Piedrafita S, Bi X, Hicks C, Yao Y, Yu C, Chaitkin E, Howison CM, Weberg L, Trouard TP, Erickson RP. Allopregnanolone treatment, both as a single injection or repetitively, delays demyelination and enhances survival of niemann-pick C mice. J Neurosci Res 2005;82:81121.
  • 87
    King SR. Emerging roles for neurosteroids in sexual behavior and function. J Androl 2008;29:52433.
  • 88
    Stoffel-Wagner B. Neurosteroid biosynthesis in the human brain and its clinical implications. Ann NY Acad Sci 2003;1007:6478.
  • 89
    VanDoren MJ, Matthews DB, Janis GC, Grobin AC, Devaud LL, Morrow AL. Neuroactive steroid 3α-hydroxy-5α-pregnan-20-one modulates electrophysiological and behavioral actions of ethanol. J Neurosci 2000;20:19829.
  • 90
    Dayanithi G, Tapia-Arancibia L. Rise in intracellular calcium via a nongenomic effect of allopregnanolone in fetal rat hypothalamic neurons. J Neurosci 1996;16:1306.
  • 91
    Poisbeau P, Feltz P, Schlicter R. Modulation of GABAA receptor-mediated IPSCs by neuroactive steroid in a rat hypothalamic-hypophyseal coculture model. J Physiol-London 1997;500:47585.
  • 92
    Poletti A, Coscarella A, Negri-Cesi P, Colciago A, Celotti F, Martini L. 5α-reductase isozymes in the central nervous system. Steroids 1998;63:24651.
  • 93
    Wetzel CH, Vedder H, Holsboer F, Zieglgansberger W, Diesz RA. Bidirectional effects of the neuroactive steroid tetrahydrocorticosterone on GABA-activated Cl- currents in cultured rat hypothalamic neurons. Br J Pharmacol 1999;127:8638.
  • 94
    Womack MD, Pyner S, Barrett-Jolley R. Inhibition of alpha-tetrahydrodeoxycorticosterone(THDOC) of pre-sympathetic parvocellular neurones in the paraventricular nucleus of rat hypothalamus. Br J Pharmacol 2006;149:6007.
  • 95
    Jain NS, Hirani K, Chopde CT. Reversal of caffeine-induced anxiety by neurosteroid 3α-hydroxy-5α-pregnane-20-one in rats. Neuropharmacology 2005;48:62738.
  • 96
    Ugale RR, Sharma AN, Kokare DM, Hirani K, Subhedar NK, Chopde CT. Neurosteroid allopregnanolone mediates anxiolytic effect of etifoxine in rats. Brain Res 2007;1184:193201.
  • 97
    Khisti RT, Chopde CT, Jain SP. Antidepressent-like effect of the neurosteroid 3α-hydroxy-5α-pregnan-20-one in mice forced swim test. Pharmacol Biochem Behav 2000;67:13743.
  • 98
    Dong E, Matsumoto K, Uzunova V, Sugaya I, Takahata H, Nomura H, Watanabe H, Costa E, Guidotti A. Brain 5alpha-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation. Proc Natl Acad Sci USA 2001;98:284954.
  • 99
    Finn DA, Beadles-Bohling AS, Beckley EH, Ford MM, Gililland KR, Gorin-Meyer RE, Wiren KM. A new look at the 5alpha-reductase inhibitor finasteride. CNS Drug Rev 2006;12:5376.
  • 100
    Uzunova V, Sampson L, Uzunov DP. Relevance of endogenous 3α-reduced neurosteroids to depression and antidepressant action. Psychopharmacology 2006;186:35161.
  • 101
    Uzunova V, Sheline I, Davis JM, Rasmusson A, Uzunova DP, Costa E, Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998;95:323944.
  • 102
    Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol 2009;29:15764.
  • 103
    Altomare G, Capella GL. Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J Dermatol 2002;29:6659.
  • 104
    Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, Mialeki A. Finasteride induced depression: A prospective study. BMC Clin Pharmacol 2006;6:7.
  • 105
    Balon R, Segraves RT. Survey of treatment practices for sexual dysfunction(s) associated with anti-depressants. J Sex Marital Ther 2008;34:35365.
  • 106
    Meston CM, Frohlich PF. The neurobiology of sexual function. Arch Gen Psychiatry 2000;57:101230.
  • 107
    Dazzi L, Serra M, Seu E, Cherchi G, Pisu G, Purdy RH, Biggio G. Progesterone enhances ethanol-induced modulation of mesocrotical dopamine neurons: Antagonism by finasteride. J Neurochem 2002;83:11039.
  • 108
    Rouge-Pont F, Mayo W, Marinelli M. The neurosteroid allopregnanolone increases dopamine release and dopaminergic response to morphine in the rat nucleus accumbens. Eur J Neurosci 2002;16:16973.
  • 109
    Charalampopoulos I, Dermitzaki E, Vardouli L, Tsatsanis C, Stournaras C, Margioris AN, Gravanis A. Dehydroepiandrosterone sulfate and allopregnanolone directly stimulate catecholamine production via induction of tyrosine hydroxylase and secretion by affecting actin polymerization. Endocrinology 2005;146:330918.
  • 110
    Bishnoi M, Chopra K, Kukkarni SK. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABAA modulating neurosteroid. Prog Neuro-Psychoph 2008;32:45161.
  • 111
    Bortolato M, Frau R, Orru M, Bourov Y, Marrosu F, Mereu G, Devoto P, Gessa GL. Antipsychotic-like properties of 5-α-reductase inhibitors. Neuropsychopharmacol 2008;33:314656.
  • 112
    Van Broekhoven F, Verkes RJ. Neurosteroids in depression: A review. Psychopharmacology (Berl) 2003;165:97110.
  • 113
    Romeo E, Ströhle A, Spalletta G, di Michele F, Hermann B, Holsboer F, Pasini A, Rupprecht R. Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 1998;155:91013.
  • 114
    Römer B, Pfeiffer N, Lewicka S, Ben-Abdallah N, Vogt MA, Deuschle M, Vollmayr B, Gass P. Finasteride treatment inhibits adult hippocampal neurogenesis in male mice. Pharmacopsychiatry 2010;43:1748.
  • 115
    Dusková M, Hill M, Hanus M, Matousková M, Stárka L. Finasteride treatment and neuroactive steroid formation. Prague Med Rep 2009;110:22230.
  • 116
    Walf AA, Sumida K, Frye CA. Inhibiting 5alpha-reductase in the amygdala attenuates antianxiety and antidepressive behavior of naturally receptive and hormone-primed ovariectomized rats. Psychopharmacology (Berl) 2006;186:30211.
  • 117
    Cohen P. Do 5-alpha reductase inhibitors influence the severity of brain injury in men after a stroke? Med Hypotheses 2010;74:956.
  • 118
    Sayeed I, Guo Q, Hoffman SW, Stein DG. Allopregnanolone, a progesterone metabolite, is more effective than progesterone in reducing cortical infarct volume after transient middle cerebral artery occlusion. Ann Emerg Med 2006;47:3819.
  • 119
    Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M, Lehtonen T, Tveter K. Can Finasteride reverse the process of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995;46:6317.
  • 120
    Nickel J, Curtis MD, Fradet Y, Boake R, Pommerville PJ. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: Results of a 2-year randomized controlled trial (the PROSPECT study). Can Med Assoc J 1996;155:12519.
  • 121
    Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, Morrill B, Wolford ET. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004;63:70915.
  • 122
    MHRA drug safety advice: Finasteride and potential risk of male breast cancer. Drug Safety Update December 2009;3:3.